Walleye Capital
MDGL icon

Walleye Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Walleye Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,300
Closed -$681K – 5012
2026
Q1 		$681K Buy
1,300
+700
+117% +$334K ﹤0.01% 2417
2025
Q4 		$349K Sell
600
-2,100
-78% -$1.07M ﹤0.01% 3193
2025
Q3 		$1.24M Buy
2,700
+2,300
+575% +$858K ﹤0.01% 1933
2025
Q2 		$121K Buy
400
+100
+33% +$29.8K ﹤0.01% 3677
2025
Q1 		$99.4K Buy
+300
New +$98.6K ﹤0.01% 3628
2024
Q3 		– Sell
-400
Closed -$112K – 5647
2024
Q2 		$112K Buy
400
+200
+100% +$47.6K ﹤0.01% 4661
2024
Q1 		$53.4K Buy
+200
New +$47.1K ﹤0.01% 4654
2023
Q2 		– Sell
-1,000
Closed -$242K – 4652
2023
Q1 		$242K Buy
+1,000
New +$272K ﹤0.01% 2307
2020
Q1 		– Sell
-900
Closed -$82K – 1372
2019
Q4 		$82K Buy
+900
New +$87.3K 0.01% 1407
2019
Q2 		– Sell
-5,400
Closed -$676K – 1916
2019
Q1 		$676K Buy
+5,400
New +$671K 0.11% 280

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's MDGL Position: Q2 2026 in Review

Walleye Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 13,227 shares — an estimated $6.78M sold.

Walleye Capital first reported a position in MDGL in Q4 2019 and held it in 6 quarters. The position peaked at $6.92M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Walleye Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 13,227 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.78M.
  • Walleye Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Walleye Capital's Madrigal Pharmaceuticals position peaked at $6.92M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.